Silence Therapeutics (SLN) Cash from Operations (2021 - 2025)
Historic Cash from Operations for Silence Therapeutics (SLN) over the last 5 years, with Q3 2025 value amounting to -$10.9 million.
- Silence Therapeutics' Cash from Operations rose 5732.03% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.5 million, marking a year-over-year decrease of 1469.48%. This contributed to the annual value of -$67.6 million for FY2024, which is 3675.14% down from last year.
- Latest data reveals that Silence Therapeutics reported Cash from Operations of -$10.9 million as of Q3 2025, which was up 5732.03% from -$21.8 million recorded in Q2 2025.
- Silence Therapeutics' 5-year Cash from Operations high stood at $36.4 million for Q2 2021, and its period low was -$27.5 million during Q4 2024.
- For the 5-year period, Silence Therapeutics' Cash from Operations averaged around -$11.4 million, with its median value being -$11.1 million (2022).
- Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 42909.49% in 2022, then surged by 6753.3% in 2024.
- Over the past 5 years, Silence Therapeutics' Cash from Operations (Quarter) stood at -$3.0 million in 2021, then plummeted by 429.09% to -$15.7 million in 2022, then crashed by 42.66% to -$22.4 million in 2023, then fell by 22.48% to -$27.5 million in 2024, then surged by 60.34% to -$10.9 million in 2025.
- Its last three reported values are -$10.9 million in Q3 2025, -$21.8 million for Q2 2025, and -$12.3 million during Q1 2025.